News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial
Amol Akhade/LinkedIn
Dec 28, 2024, 11:14

Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial

Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X:

“Tislelizumab gets FDA approval for Metastatic Gastric or GE junction adenocarcinoma Her2 negative with PDL1 More than 1 %. This is based upon rationale 305 trial. One more option of IO in this space where pembrolizumab and nivo are already approved irrespective of PDL1.”

Read Further.

Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. 

305 trial Amol Akhade cancer FDA gastric cancer GE junction adenocarcinoma OncoDaily Oncology Suyog Cancer Clinics and Reliance Hospitals Tislelizumab
Special Coverage
Blog
Dec 28, 2024, 11:18
A New Generation of Patient-Centric Cancer Clinical Trials - AACR
Science
Dec 28, 2024, 11:14
Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial
Blog
Dec 28, 2024, 11:11
Diving into the inspiring and challenging world of being a cancer researcher - EACR
Blog
Dec 28, 2024, 11:05
Andrea Necchi: The Financial Burden of Localized and Metastatic Bladder Cancer
Blog
Dec 28, 2024, 10:55
Clare Dowling Dougherty: Honored to be represented in Media planet's Breast Health Campiagn
Blog
Dec 28, 2024, 10:49
Season's Greetings from National Cancer Audit Collaborating Centre
Blog
Dec 28, 2024, 10:39
Meet the AIEOP's 2024-2027 Board Of Directors: President, Angela Mastronuzzi
Insight
Dec 28, 2024, 10:35
Submit an abstract by December 30 for the AACR Special Conference on ALL
Blog
Dec 28, 2024, 10:25
Joe Lennerz: A pivotal moment in the ongoing debate over FDA’s regulation of LDTs
Science
Dec 28, 2024, 09:40
5 papers about Lung Cancer suggested by Stephen Liu
Insight
Dec 28, 2024, 09:33
Guangzhou has Launched Comprehensive Breast Cancer Cohort to Enhance Personalized Prevention
Blog
Dec 28, 2024, 09:25
Alma Sanchez Jimenez: Registration is open for 2025 PPCR Course